Biotechnology company Transgene Biotek today said it has entered into a licensing and technology transfer agreement with Portugal-based Atral Cipan for its immunosuppressive drug Tacrolimus.
As a result of this agreement, Atral Cipan will move the product through regulatory filings with the US Food and Drug Administration (USFDA) and European Medicines Agency (EMEA) for the manufacturing and marketing of Tacrolimus.
“The agreement provides the basis for the manufacture, commercialisation and marketing of the immune—suppressant drug Tacrolimus using technology developed and transferred by Transgene Biotek,” the company said.
The companies believe that the agreement would help in expanding the commercialisation and marketing of Tacrolimus across developed markets including the US and Europe, it added.
Tacrolimus is used along with other medications to prevent rejection in people who have received kidney, liver, or heart transplants.
It works by decreasing the activity of the immune system to prevent it from attacking the transplanted organ.